{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T02:37:41Z","timestamp":1773283061436,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA008748"],"award-info":[{"award-number":["P30CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.modpat.2023.100150","type":"journal-article","created":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T12:34:01Z","timestamp":1677242041000},"page":"100150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Loss of CDKN2A\/B is a Molecular Marker of High-grade Histology and is Associated with Aggressive Behavior in Acinic Cell Carcinoma"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4905-8946","authenticated-orcid":false,"given":"Snjezana","family":"Dogan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satshil","family":"Rana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald A.","family":"Ghossein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael F.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan L.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nora","family":"Katabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.modpat.2023.100150_bib1","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1007\/s00405-015-3855-7","article-title":"Salivary acinic cell carcinoma: reappraisal and update","volume":"273","author":"Vander Poorten","year":"2016","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"10.1016\/j.modpat.2023.100150_bib2","series-title":"World Health Organization Classification of Head and Neck Tumours","first-page":"166","author":"El-Naggar","year":"2017"},{"key":"10.1016\/j.modpat.2023.100150_bib3","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1001\/jamaoto.2013.4728","article-title":"Prognostic factors associated with decreased survival in patients with acinic cell carcinoma","volume":"139","author":"Neskey","year":"2013","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.modpat.2023.100150_bib4","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/lary.24231","article-title":"Demographic trends and disease-specific survival in salivary acinic cell carcinoma: an analysis of 1129 cases","volume":"124","author":"Patel","year":"2014","journal-title":"Laryngoscope"},{"key":"10.1016\/j.modpat.2023.100150_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2019.152767","article-title":"Ten patients with high-grade transformation of acinic cell carcinomas: expression profiling of \u03b2-catenin and cyclin D1 is useful","volume":"216","author":"Yue","year":"2020","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.modpat.2023.100150_bib6","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s12105-015-0645-x","article-title":"Clinicopathologic and immunophenotypic characterization of 25 cases of acinic cell carcinoma with high-grade transformation","volume":"10","author":"Thompson","year":"2016","journal-title":"Head Neck Pathol"},{"key":"10.1016\/j.modpat.2023.100150_bib7","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1177\/019459988809800210","article-title":"Dedifferentiated acinic cell (acinous) carcinoma of the parotid gland","volume":"98","author":"Stanley","year":"1988","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.modpat.2023.100150_bib8","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1002\/cncr.24259","article-title":"Clinical and pathologic prognostic features in acinic cell carcinoma of the parotid gland","volume":"115","author":"Gomez","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.modpat.2023.100150_bib9","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1097\/PAS.0000000000001867","article-title":"Head and Neck Acinic Cell Carcinoma: A new grading system proposal and diagnostic utility of NR4A3 immunohistochemistry","volume":"46","author":"Xu","year":"2022","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.modpat.2023.100150_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-08069-x","article-title":"Enhancer hijacking activates oncogenic transcription factor NR4A3 in acinic cell carcinomas of the salivary glands","volume":"10","author":"Haller","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.modpat.2023.100150_bib11","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1097\/PAS.0000000000001279","article-title":"Nuclear NR4A3 immunostaining is a specific and sensitive novel marker for acinic cell carcinoma of the salivary glands","volume":"43","author":"Haller","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.modpat.2023.100150_bib12","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.jtho.2019.02.008","article-title":"PD-L1 expression, tumor mutational burden, and cancer gene mutations are stronger predictors of benefit from immune checkpoint blockade than HLA class I genotype in non\u2013small cell lung cancer","volume":"14","author":"Negrao","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.modpat.2023.100150_bib13","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.modpat.2023.100150_bib14","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nbt.2696","article-title":"Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing","volume":"31","author":"Frampton","year":"2013","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.modpat.2023.100150_bib15","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","article-title":"Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology","volume":"17","author":"Cheng","year":"2015","journal-title":"J\u00a0Mol Diagn"},{"key":"10.1016\/j.modpat.2023.100150_bib16","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.modpat.2023.100150_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00011","article-title":"OncoKB: A precision oncology knowledge base","volume":"2017","author":"Chakravarty","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.modpat.2023.100150_bib18","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/his.13944","article-title":"The immune microenvironment and expression of PD-L1, PD-1, PRAME and MHC I in salivary duct carcinoma","volume":"75","author":"Xu","year":"2019","journal-title":"Histopathology"},{"key":"10.1016\/j.modpat.2023.100150_bib19","first-page":"720","article-title":"Targeted therapy, chemotherapy, immunotherapy and novel treatment options for different subtypes of salivary gland cancer","volume":"11","author":"Mueller","year":"2022","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.modpat.2023.100150_bib20","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.oraloncology.2012.02.021","article-title":"The PI3K\/AKT\/mTOR signalling pathway is active in salivary gland cancer and implies different functions and prognoses depending on cell localisation","volume":"48","author":"Ettl","year":"2012","journal-title":"Oral Oncol"},{"key":"10.1016\/j.modpat.2023.100150_bib21","article-title":"Clinicopathological and targeted exome gene features of a patient with metastatic acinic cell carcinoma of the parotid gland harboring an ARID2 nonsense mutation and CDKN2A\/B deletion","volume":"2015","author":"Warner","year":"2015","journal-title":"Case Rep Oncol Med"},{"key":"10.1016\/j.modpat.2023.100150_bib22","article-title":"A\u00a0case report and genetic characterization of a massive acinic cell carcinoma of the parotid with delayed distant metastases","author":"Nichols","year":"2013","journal-title":"Case Rep Oncol Med"},{"key":"10.1016\/j.modpat.2023.100150_bib23","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/gcc.20719","article-title":"Unfavorable prognosis of CRTC1-MAML2 positive mucoepidermoid tumors with CDKN2A deletions","volume":"49","author":"Anzick","year":"2010","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.modpat.2023.100150_bib24","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1093\/neuonc\/noz126.000","article-title":"CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas","volume":"21","author":"Appay","year":"2019","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.modpat.2023.100150_bib25","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2009-10-247122","article-title":"Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study","volume":"116","author":"Jardin","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.modpat.2023.100150_bib26","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1002\/ijc.25432","article-title":"Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: cohort study and literature review","volume":"128","author":"Shima","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.modpat.2023.100150_bib27","first-page":"960","article-title":"CDKN2A\/B loss in high-grade transformation of salivary gland carcinoma: high-grade malignant potential in histologically low-grade component. United States & Canadian Academy of Pathology 111th Annual Meeting Abstracts: Head and Neck Pathology (800-850)","volume":"35","author":"Nakaguro","year":"2022","journal-title":"Mod Pathol"},{"key":"10.1016\/j.modpat.2023.100150_bib28","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00401-020-02188-w","article-title":"CDKN2A\/B homozygous deletion is associated with early recurrence in meningiomas","volume":"140","author":"Sievers","year":"2020","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.modpat.2023.100150_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.988527","article-title":"Effect of comprehensive cancer genomic profiling on therapeutic strategies and clinical outcomes in patients with advanced biliary tract cancer: a prospective multicenter study","volume":"12","author":"Takada","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.modpat.2023.100150_bib30","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.oraloncology.2017.07.030","article-title":"Role of CDKN2A\/p16 expression in the prognostication of oral squamous cell carcinoma","volume":"73","author":"Padhi","year":"2017","journal-title":"Oral Oncol"},{"key":"10.1016\/j.modpat.2023.100150_bib31","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1093\/jnci\/djx271","article-title":"Tumor CDKN2A-associated JAK2 loss and susceptibility to immunotherapy resistance","volume":"110","author":"Horn","year":"2018","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.modpat.2023.100150_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-021-99524-1","article-title":"CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer","volume":"11","author":"Gutiontov","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.modpat.2023.100150_bib33","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1158\/2159-8290.CD-20-1638","article-title":"Overcoming resistance to tumor-targeted and immune-targeted therapies","volume":"11","author":"Aldea","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.modpat.2023.100150_bib34","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1200\/PO.20.00037","article-title":"Palbociclib in patients with non\u2013small-cell lung cancer with CDKN2A alterations: results from the targeted agent and profiling utilization registry study","volume":"4","author":"Ahn","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.modpat.2023.100150_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.880153","article-title":"Combining a CDK4\/6 inhibitor with pemetrexed inhibits cell proliferation and metastasis in human lung adenocarcinoma","volume":"12","author":"Ke","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.modpat.2023.100150_bib36","article-title":"Clinical utility of CDK4\/6 inhibitors in sarcoma: successes and future challenges","volume":"6","author":"Hsu","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.modpat.2023.100150_bib37","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.modpat.2023.100150_bib38","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.eururo.2020.10.029","article-title":"Advanced prostate cancer with ATM loss: PARP and ATR inhibitors","volume":"79","author":"Neeb","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.modpat.2023.100150_bib39","article-title":"Genomic analysis of exceptional responders to radiotherapy reveals somatic mutations in ATM","volume":"8","author":"Ma","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.modpat.2023.100150_bib40","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s43018-021-00218-4","article-title":"The present and future of PI3K inhibitors for cancer therapy","volume":"2","author":"Castel","year":"2021","journal-title":"Nat Cancer"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395223000558?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395223000558?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T01:23:08Z","timestamp":1760232188000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395223000558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S0893395223000558"],"URL":"https:\/\/doi.org\/10.1016\/j.modpat.2023.100150","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Loss of CDKN2A\/B is a Molecular Marker of High-grade Histology and is Associated with Aggressive Behavior in Acinic Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.modpat.2023.100150","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 United States & Canadian Academy of Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100150"}}